Back to search
FDAFDA · Food and drugs·Recall number D-0988-2018

Valsartan Tablets, USP 160 mg, 90-count bottle (NDC 0591-2169-19), 1000-count bottle (NDC 0591-2169-10), Rx Only, Rx Only, Manufactured by: Arrow Pharma (Malta) Ltd. India, Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054

Published August 1, 2018 · Recall initiated: July 16, 2018

Summary

FDA records drug Class II recall D-0988-2018, published August 1, 2018 and initiated July 16, 2018. Recalling firm: Teva Pharmaceuticals USA; Status: Ongoing; Reported quantity: 15,347 90-count bottles, 8,378 1000-count bottles; Lot: NDC 0591-2169-19 Lot Numbers: 1177880A, 1220831A, 1263941A NDC 0591-2169-10 1175922M, 1220826M, 1236294M, 1240427M, 1270616A. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Product was distributed throughout the United States, including Hawaii and Puerto Rico
Lot
NDC 0591-2169-19 Lot Numbers: 1177880A, 1220831A, 1263941A NDC 0591-2169-10 1175922M, 1220826M, 1236294M, 1240427M, 1270616A
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Valsartan Tablets, USP 160 mg, 90-count bottle (NDC 0591-2169-19), 1000-count bottle (NDC 0591-2169-10), Rx Only, Rx Only, Manufactured by: Arrow Pharma (Malta) Ltd. India, Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 recalled?

Yes. FDA published recall D-0988-2018 on August 1, 2018. Reported hazard: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release